Status: Recruiting
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Participants needed: 7,500
Trial details
Age: 55+Biological sex: AllType: InterventionalSponsor: Cleerly, Inc.Updated: Jun 16, 2026Locations: 124
Eligibility criteria
Provided electronic or written informed consent [+7]
History of symptomatic CVD defined as prior MI, exertional or unstable angina, i... [+10]